FATE Company Profile and Key Details

Q: Who are the executives of FATE?

Dr. Bahram Valamehr Ph.D.Chief R&D OfficerMs. Cindy R. TahlGen. Counsel & Corporation Sec.Mr. Jim Beitel M.B.A.Senior Vice President of Corporation Devel.Mr. Edward J. Dulac IIIChief Financial OfficerDr. Mark Plavsic D.V.M., Ph.D.Chief Technical OfficerDr. Sarah CooleySenior Vice President of Clinical TranslationMr. Brian T. Powl M.B.A., M.S.Chief Commercial OfficerDr. Jerome Bressi Ph.D.Senior Vice President of Regulatory & QualityMr. J. Scott WolchkoFounder, Chief Executive Officer, Pres & DirectorDr. Yu-Waye Chu M.D.Chief Medical Officer

NASDAQ : FATE

Fate Therapeutics

$1.76

-0.145-7.63%

At Close 4:00 PM

58.9

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Fate Therapeutics, Inc. (FATE) stock declined over -7.63%, trading at $1.76 on NASDAQ, down from the previous close of $1.90. The stock opened at $1.86, fluctuating between $1.71 and $1.91 in the recent session.

Stock Snapshot

1.9

Prev. Close

204.56M

Market Cap

1.71

Day Low

-1.61

P/E Ratio

-1.09

EPS (TTM)

-1.4

Cash Flow per Share

1.86

Open

116.56M

Number of Shares

1.91

Day High

87.4%

Free Float in %

3.74

Book Value

2.06M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 15, 2026	1.86	1.91	1.71	1.76	2.06M
May 14, 2026	2.02	2.20	1.90	1.90	3.76M
May 13, 2026	2.19	2.22	1.83	2.13	5.38M
May 12, 2026	2.19	2.27	2.06	2.25	2.1M
May 11, 2026	2.36	2.43	2.15	2.18	3.42M
May 08, 2026	2.40	2.47	2.32	2.39	2.54M
May 07, 2026	2.25	2.47	2.10	2.43	4.37M
May 06, 2026	2.40	2.41	2.16	2.29	5.86M
May 05, 2026	2.05	2.36	1.98	2.36	10.64M
May 04, 2026	1.54	1.88	1.53	1.80	8.62M
Apr 30, 2026	1.22	1.28	1.22	1.25	741.45K
Apr 29, 2026	1.28	1.30	1.22	1.24	909.81K
Apr 28, 2026	1.30	1.34	1.28	1.30	737.03K
Apr 27, 2026	1.36	1.38	1.30	1.31	1.35M
Apr 23, 2026	1.37	1.39	1.30	1.32	989.31K
Apr 22, 2026	1.39	1.40	1.36	1.37	700.88K
Apr 21, 2026	1.40	1.40	1.32	1.35	1.21M
Apr 20, 2026	1.38	1.41	1.35	1.39	1.2M
Apr 17, 2026	1.40	1.42	1.35	1.39	2.02M
Apr 16, 2026	1.28	1.39	1.28	1.37	1.23M

Contact Details

San Diego, CA 92131

United States

https://www.fatetherapeutics.com 858 875 1800

About Company

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Stock Peers

ARGX

-22.81-2.77%

argenx SE$799.32 REGN

-14.62-2.05%

Regeneron Pharmaceuticals, Inc.$698.25 UTHR

-7.21-1.25%

United Therapeutics Corporation$568.58 MDGL

-16.2-3.00%

Madrigal Pharmaceuticals, Inc.$523.69 VRTX

-13.46-2.99%

Vertex Pharmaceuticals Incorporated$436.95 PRAX

-2.94-0.85%

Praxis Precision Medicines, Inc.$342.58 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

-10.01-3.16%

Krystal Biotech, Inc.$306.29 ALNY

-6.47-2.20%

Alnylam Pharmaceuticals, Inc.$286.98 ASND

-4.99-2.03%

Ascendis Pharma A/S$240.50

Company Overview

Fate Therapeutics, Inc. (NASDAQ:FATE) closed at $1.75 USD, losing -$0.15 (-7.63%) from the previous close of $1.90. The stock is currently mid-range between its 52-week high and low $0.91 and $2.47. With a market capitalization of about $204.56 million, Fate Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.14). Key stats such as the average daily volume over the past year has been around 2.06 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Fate Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bahram Valamehr, the company employs approximately 181 people and listed since October 01, 2013. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

Technical Performance

FATE has shown mixed momentum, gaining 2.8% over the past week and -25.17% over the past quarter, though year-to-date performance is up 11.95%. Short-term trend indicators are mixed aligned (SMA20 21.5%, SMA50 34.1%, SMA200 33.46%). The stock’s 14-day RSI is 66.51 (firm momentum), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.58% below its high and over 135.99% above its low. Average 10-day trading volume of 3.69 million shares is significantly above the 3-month average of 2.06 million, indicating heightened recent market interest.

Valuation Metrics

Fate Therapeutics, Inc. trades at a P/E ratio of -1.59, slightly below the S&P 500 average, with a price-to-sales ratio of 31.8 and a price-to-book ratio of 1.15 suggesting the stock is closer to book value. The P/FCF stands at -1.86, also above market averages.

Dividend & Fair Value

Fate Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.56. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Fate Therapeutics, Inc. generated EPS of -$1.32 over the past year. Five-year average earnings growth is -2.63%. Wall Street analysts project EPS growth of 10.62% annually over the next five years. The latest quarter delivered EPS of -$0.26. The next quarter is forecast at -$0.27. Next year's EPS is expected at -$16.59. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $2.50. The high target offers 300.0% upside. The low target suggests 42.86% downside. The mean target is $5.38. This offers 207.43% upside. Fate Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 13, 2026, missed forecasts by -13.33%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -29.55% in March 05, 2025.

Shareholding & Insider Activity

Fate Therapeutics, Inc. has 115.33 million shares outstanding. The public float is 100.80 million shares, elevated short interest at 9.24% of float. This equals 9.28 million shares. The short ratio is 6.34 days. Institutional investors hold 80.04% of the float. Insiders own 1.71%. Redmile Group, LLC holds 12.49 million shares, TAHL CINDY has 387.08 thousand shares and Wolchko J Scott has 371.25 thousand shares. Over the past six months, insider transactions show net selling. They sold 15.78 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Fate Therapeutics generated $63.53M in revenue, or $0.65 per share. Gross margin was 71.22%, operating margin -279.56%, and net profit margin -253.30%. Returns are negative, with ROA at -31.79% and ROE at -43.68%.
On valuation metrics, Fate Therapeutics trades at a P/E of -1.59, P/S of 31.80 and P/B of 1.15. The current ratio is 5.85 and quick ratio is 5.85. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -369.22 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.43, supported by a cash flow-to-debt ratio of -1.34.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Fate Therapeutics posted revenue of $63.53M, down slightly from $96.30M in the prior quarter. Gross profit was $45.25M (margin 71.22%). Operating income was - $177.61M (margin -279.6%). Net income was- $160.93M (EPS - $1.64).
The company ended the quarter with $315.18M in cash and short-term investments, a total debt of $103.54M, and net debt of $61.67M. Total assets were $506.22M, with equity of $368.42M. Financials further reflected weakness, with operating cash flow of - $132.26M, free cash flow of - $138.42M, and capital expenditures of - $6.15M.

Price Forecast & Outlook

Our AI price prediction model suggests that Fate Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 25.57%, with price expected at $2.21 by May 29, 2026, within a range of $1.90 to $2.52 3-Month Outlook: Projected rise of 42.05%, reaching $2.50 by August 13, 2026, with a range of $2.42 to $2.59. 1-Year Outlook: Projected gain of 411.93%, with price at $9.01 by May 14, 2027, within a range of $0.00 to $12.19.

Key Takeaways

Fate Therapeutics, Inc. (NASDAQ:FATE) shares are up 11.95% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Fate Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.59. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $30.94, suggesting 1657.95% upside. Our AI forecast model points to short-term strength (25.57% over two weeks), a medium-term rise (42.05% over three months), and a longer-term gain (411.93% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Fate Therapeutics, Inc. (FATE) stock price?

Fate Therapeutics, Inc. (NASDAQ: FATE) stock price is $1.76 in the last trading session. During the trading session, FATE stock reached the peak price of $1.91 while $1.71 was the lowest point it dropped to. The percentage change in FATE stock occurred in the recent session was -7.63% while the dollar amount for the price change in FATE stock was - $0.15.

FATE's industry and sector of operation?

The NASDAQ listed FATE is part of Biotechnology industry that operates in the broader Healthcare sector. Fate Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of FATE?

Dr. Bahram Valamehr Ph.D.
Chief R&D Officer
Ms. Cindy R. Tahl
Gen. Counsel & Corporation Sec.
Mr. Jim Beitel M.B.A.
Senior Vice President of Corporation Devel.
Mr. Edward J. Dulac III
Chief Financial Officer
Dr. Mark Plavsic D.V.M., Ph.D.
Chief Technical Officer
Dr. Sarah Cooley
Senior Vice President of Clinical Translation
Mr. Brian T. Powl M.B.A., M.S.
Chief Commercial Officer
Dr. Jerome Bressi Ph.D.
Senior Vice President of Regulatory & Quality
Mr. J. Scott Wolchko
Founder, Chief Executive Officer, Pres & Director
Dr. Yu-Waye Chu M.D.
Chief Medical Officer

How FATE did perform over past 52-week?

FATE's closing price is 92.86% higher than its 52-week low of $0.91 where as its distance from 52-week high of $2.47 is -28.95%.

How many employees does FATE have?

Number of FATE employees currently stands at 181.

Link for FATE official website?

Official Website of FATE is: https://www.fatetherapeutics.com

How do I contact FATE?

FATE could be contacted at phone 858 875 1800 and can also be accessed through its website. FATE operates from 12278 Scripps Summit Drive, San Diego, CA 92131, United States.

How many shares of FATE are traded daily?

FATE stock volume for the day was 2.06M shares. The average number of FATE shares traded daily for last 3 months was 2.06M.

What is the market cap of FATE currently?

The market value of FATE currently stands at $204.56M with its latest stock price at $1.76 and 116.56M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	181
Beta	2.23
Sales or Revenue	$63.53M
5Y Sales Change%	6.654%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

FATE Company Profile and Key Details

Fate Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Valuation Metrics

Price Forecast & Outlook